Moderna (NASDAQ:MRNA) Upgraded at HSBC

HSBC upgraded shares of Moderna (NASDAQ:MRNA - Free Report) from a hold rating to a buy rating in a research note published on Monday, Marketbeat reports. HSBC currently has $58.00 price objective on the stock.

MRNA has been the topic of several other research reports. JPMorgan Chase & Co. cut their price objective on Moderna from $70.00 to $59.00 and set an "underweight" rating on the stock in a report on Monday, November 4th. Sanford C. Bernstein initiated coverage on shares of Moderna in a report on Thursday, October 17th. They issued a "market perform" rating and a $55.00 price target on the stock. TD Cowen decreased their price objective on Moderna from $70.00 to $60.00 and set a "hold" rating for the company in a report on Friday, September 13th. Bank of America dropped their target price on Moderna from $130.00 to $110.00 and set a "neutral" rating on the stock in a report on Friday, September 13th. Finally, Hsbc Global Res raised Moderna from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 28th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $86.33.

Moderna Trading Up 7.2 %

MRNA traded up $2.66 during trading hours on Monday, reaching $39.51. 13,447,142 shares of the company's stock traded hands, compared to its average volume of 4,749,606. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $58.56 and a 200 day moving average price of $96.68. Moderna has a 52-week low of $35.80 and a 52-week high of $170.47. The firm has a market capitalization of $15.20 billion, a PE ratio of -6.70 and a beta of 1.69.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business's revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the prior year, the business posted ($1.39) earnings per share. As a group, sell-side analysts predict that Moderna will post -9.43 EPS for the current fiscal year.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

Hedge funds have recently made changes to their positions in the stock. Intrinsic Value Partners LLC lifted its stake in Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company's stock worth $3,435,000 after purchasing an additional 24,505 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Moderna by 11.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company's stock worth $107,885,000 after purchasing an additional 167,596 shares during the period. Vontobel Holding Ltd. lifted its position in shares of Moderna by 148.2% during the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company's stock worth $7,758,000 after purchasing an additional 69,313 shares in the last quarter. Profund Advisors LLC grew its holdings in shares of Moderna by 20.9% in the second quarter. Profund Advisors LLC now owns 56,218 shares of the company's stock valued at $6,676,000 after purchasing an additional 9,719 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Moderna by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company's stock worth $25,359,000 after buying an additional 15,218 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.